Molecular Advances in Lung Cancer: From Pathogenesis to Precision Therapy (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 2084
Special Issue Editor
Interests: epigenetics; molecular biology; lung cancer; DNA methylation; resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Following the success of our previous Special Issue, “Molecular Advances in Lung Cancer: From Pathogenesis to Precision Therapy” (https://www.mdpi.com/journal/cancers/special_issues/41R029SP49), we are pleased to announce its second edition in Cancers. This Issue will comprehensively examine the molecular landscape of lung cancer, bridging fundamental discoveries with clinical applications in precision medicine.
Lung cancer represents a complex and heterogeneous disease driven by diverse molecular alterations. While targeted therapies against EGFR, ALK, ROS1, KRAS, and other oncogenic drivers have revolutionized treatment, emerging research continues to uncover novel molecular mechanisms underlying tumor initiation, progression, and therapeutic resistance. This Special Issue will highlight cutting-edge advances across the entire spectrum of lung cancer research, including the following:
- Molecular pathogenesis: Oncogenic signaling pathways and tumor microenvironment interactions, epigenetic regulation and non-coding RNAs in lung carcinogenesis, and molecular subtypes and tumor heterogeneity;
- Diagnostic innovations: Novel biomarkers for early detection and minimal residual disease, liquid biopsy and next-generation sequencing technologies, and computational approaches for molecular profiling;
- Therapeutic advances: Development of targeted therapies (TKIs, antibody–drug conjugates, etc.), immunotherapy resistance mechanisms and combination strategies, and emerging targets (e.g., MET exon 14, RET, NRG1, HER2);
- Translational and clinical research: Biomarker-guided clinical trial design, real-world evidence for molecularly matched therapies, and strategies to overcome therapeutic resistance.
We invite original research articles and reviews that contribute to these themes. This Special Issue will provide a platform for multidisciplinary research ranging from basic science to clinical applications, with the ultimate goal of improving outcomes for lung cancer patients worldwide. All submissions will undergo rigorous peer review to ensure scientific excellence.
We look forward to receiving your valuable contributions to this endeavor.
Sincerely,
Dr. Federico Pio Fabrizio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer molecular biology
- targeted therapy
- precision medicine
- biomarkers
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
